Low-dose digoxin cuts heart failure hospitalizations by 25%
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UMCG cardiologists led three studies on low-dose digoxin, enrolling 1,000 heart-failure patients across 43 Netherlands centers, with half receiving digoxin alongside standard treatment for an average of three years.
- The digoxin group saw heart-failure hospitalizations fall by 25% versus placebo; cardiovascular deaths and worsening heart failure dropped 19%, though that result only reached statistical significance once combined with two earlier studies in a meta-analysis.
- A third study tracking roughly 600 participants found that patients who stopped digoxin had significantly more health problems in the first six weeks — 14 of 288 were hospitalized or died.
- Digoxin costs less than ten cents per day, compared to several euros daily for newer heart-failure medications, yet currently only about 15% of heart-failure patients receive it.
- The findings were published in Nature Medicine and JAMA and presented at the ESC Heart Failure Congress in Barcelona, with researchers saying they could eventually influence heart-failure treatment guidelines and add digoxin to the existing 'Fantastic Four' standard regimen.
- Hartstichting provided 3 million euros through ZonMw's Good Use of Medicines program, underscoring how studies on older, inexpensive drugs struggle to attract mainstream funding.
Why it matters: For the more than 500,000 people in the Netherlands with heart failure — and many millions globally — a drug costing under ten cents a day that cuts hospitalizations by 25% presents a rare case of low-cost, high-impact medicine. If added as a fifth therapy to the standard 'Fantastic Four' regimen, digoxin could ease treatment costs (cents vs. several euros daily) and reshape clinical guidelines that currently relegate it to just 15% of patients.
Ask SkimNews
